What medication can be given for a patient in acute opioid withdrawal?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Medications for Acute Opioid Withdrawal

For moderate to severe acute opioid withdrawal (COWS >8), give buprenorphine 4-8 mg sublingually as the first-line treatment, as it provides superior symptom relief, fewer adverse effects, and better treatment retention compared to all other options. 1

Treatment Algorithm Based on Withdrawal Severity

Step 1: Assess Withdrawal Severity Using COWS Score

Mild withdrawal (COWS <8):

  • No buprenorphine indicated initially
  • Reassess in 1-2 hours
  • Use symptomatic management (see below)

Moderate to severe withdrawal (COWS ≥8):

  • Administer buprenorphine 4-8 mg sublingually based on severity
  • Reassess after 30-60 minutes
  • Target total daily dose of 16 mg for most patients 1

Step 2: Confirm Timing Since Last Opioid Use

This is critical to avoid precipitated withdrawal with buprenorphine:

  • Short-acting opioids (heroin, morphine IR): >12 hours since last use
  • Extended-release formulations (OxyContin): >24 hours since last use
  • Methadone maintenance patients: >72 hours since last use (consider methadone instead of buprenorphine in these patients) 1

Important caveat: Fentanyl may require >12 hours despite being short-acting due to tissue accumulation 2

Medication Options by Efficacy

First-Line: Buprenorphine (Most Effective)

Buprenorphine is the most effective treatment based on meta-analyses showing it produces less severe withdrawal symptoms, fewer adverse effects, and longer treatment retention compared to clonidine, lofexidine, or methadone 1.

Dosing:

  • Initial: 4-8 mg sublingual
  • Reassess after 30-60 minutes
  • Target 16 mg total on day 1 for most patients
  • Can prescribe up to 3 days without X-waiver (now eliminated as of 2023) 1, 2

Critical pitfall: Buprenorphine can precipitate withdrawal if given too soon after full agonist use due to its partial agonist properties displacing full agonists from receptors 3

Second-Line: Methadone (Effective but Restricted)

Methadone is similarly effective to buprenorphine for withdrawal but has significant practical limitations 1. While physicians can administer methadone in the ED/hospital for up to 72 hours without an opioid treatment program, its long duration of action (hours to days) and potential to interfere with ongoing treatment programs make it less commonly used 1.

When to consider methadone:

  • Patients on methadone maintenance (>72 hours since last dose)
  • Patients who cannot tolerate or fail buprenorphine
  • Starting dose: 30-40 mg/day prevents withdrawal in most patients 4

Third-Line: Symptomatic Management with Non-Opioids

When opioid agonist therapy is unavailable, declined, or contraindicated, use combination symptomatic treatment 1:

α2-Adrenergic agonists (most important non-opioid option):

  • Clonidine or lofexidine for autonomic symptoms
  • Only use in non-hypotensive patients
  • These are less effective than buprenorphine but superior to other non-opioid options 5

Adjunctive medications:

  • Antiemetics (promethazine) for nausea/vomiting
  • Benzodiazepines to reduce catecholamine release, muscle cramps, and anxiety
  • Loperamide for diarrhea
  • Gabapentin, hydroxyzine, muscle relaxants as additional adjuncts 1, 6

Key Clinical Considerations

Regarding naltrexone: This is NOT appropriate for acute withdrawal as it precipitates severe withdrawal in opioid-dependent patients and requires 7-10 days of abstinence before administration 3

Regarding short-acting full agonist opioids (SAFAOs): Emerging evidence suggests hydromorphone, oxycodone, or fentanyl may be useful adjuncts when methadone/buprenorphine are insufficient, particularly with high-potency fentanyl tolerance, but this remains investigational and carries oversedation risks 7, 8

Harm reduction essentials: Always provide overdose prevention education, prescribe take-home naloxone, and offer hepatitis C/HIV screening regardless of which withdrawal medication is chosen 1

Why Buprenorphine is Superior

The 2020 ACEP guidelines 1 synthesize multiple meta-analyses demonstrating buprenorphine's superiority stems from:

  1. More complete symptom relief than α2-agonists
  2. Safer respiratory depression profile than methadone (ceiling effect)
  3. Ability to initiate medication for opioid use disorder simultaneously
  4. Better treatment retention and reduced mortality long-term

The evidence is clear: buprenorphine should be the default choice for moderate-severe withdrawal unless specific contraindications exist (too soon after full agonist use, patient on methadone maintenance, or patient preference). 1

Related Questions

What is the appropriate management plan for a patient with active opioid (Norco) addiction, recent withdrawal, dangerous behavior (walking into traffic), and possible quetiapine (Seroquel) side effects (transient vision changes and lower‑extremity weakness), who is requesting an urgent appointment, given her comorbidities of migraines, sleep apnea, sinus problems, fibromyalgia, restless‑leg syndrome, irritable bowel syndrome, and asthma, and current medications Dulera (fluticasone/salmeterol), Relpax (eletriptan), Zofran (ondansetron), Singulair (montelukast), trazodone, omeprazole, ibuprofen, and Lyrica (pregabalin)?
What is the appropriate management for hypertension and syncope caused by opioid withdrawal?
Could the severe vomiting after the first Subutex (buprenorphine) dose in an opioid detox patient be due to administering the medication too early or giving a dose that is too high?
How should a short-acting cardio-selective β‑blocker be used as adjunct therapy for tachycardia and hypertension in an adult undergoing simultaneous alcohol and opioid withdrawal, including dosing, contraindications, and monitoring?
What medication is recommended for treating clonidine withdrawal?
Is RSV vaccination recommended for a healthy 11‑month‑old infant?
When performing emergency endotracheal intubation with intravenous midazolam and vecuronium, what precautions and optimal timing should be used compared with rocuronium, should the vecuronium dose be increased and to what amount, what are the associated risks (e.g., aspiration, laryngospasm, prolonged paralysis), why should an orogastric or nasogastric decompression tube be placed immediately after intubation, what are the most common maintenance infusion rates for fentanyl and propofol, and is a fentanyl infusion alone sufficient for analgosedation or is a hypnotic agent also required?
What is the recommended initial test to diagnose a colonic fistula?
What is the appropriate dose of activated charcoal for a patient who ingested candesartan?
Does calcitriol lower serum calcium?
What are the recommended dosing, administration, side effects, and monitoring for oral iron therapy in iron‑deficiency anemia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.